A new non-NMDA antagonist modifies the local cerebral glucose utilization in kainate-induced generalized seizure.
To investigate the effects of a new non-NMDA antagonist on the trisynaptic pathways in the hippocampus, the author examined the kainate(KA)-induced generalized seizures in rats. A novel non-NMDA antagonist, YM90K, showed the blockade of the Schaffer collaterals in a 2-deoxyglucose study (2-DG) and that the CA1-2 pyramidal cells of the hippocampus were preserved seven days after the KA injections. On the other hand, the control and MK-801 (NMDA-antagonist) treated rats did not depress the Schaffer collaterals and showed persistent hypermetabolism of glucose in the CA1 pyramidal cell layer, where neurons were not preserved seven days later. 2-DG was useful to reveal the effects of a non-NMDA antagonist on the KA-induced generalized seizures. This suggests that YM90K is a potent non-NMDA antagonist and that it has a neuroprotective effect in rats.
Shiraishi
K
K
Department of Neurosurgery, Soga Clinic, Hokkaido, Japan.
D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology*; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D016291:Dizocilpine Maleate / Q000494:pharmacology; D005947:Glucose / Q000378:metabolism*; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism; D007608:Kainic Acid; D008297:Male; D016202:N-Methylaspartate / Q000037:antagonists & inhibitors; D011810:Quinoxalines / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012640:Seizures / Q000139:chemically induced / Q000378:metabolism*
D000927:Anticonvulsants; D011810:Quinoxalines; C086162:6-(1H-imidazol-1-yl)-7-nitro-2,3(1H,4H)-quinoxalinedione; D016202:N-Methylaspartate; D016291:Dizocilpine Maleate; D005947:Glucose; D007608:Kainic Acid